ABMD ABIOMED, Inc. featured news, full reports, and detailed charts
ABIOMED, Inc. (ABMD) Wrap Up:
We are a leading provider of medical devices in circulatory support and offer a continuum of care in heart recovery to acute heart failure patients. Our strategy is focused on establishing heart recovery as the goal for all acute cardiac attacks. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. We believe we are the only company with commercially available cardiac assist devices approved for heart recovery by the Food and Drug Administration, or FDA, and our products have been used to treat thousands of patients to date. Our products can be used in a broad range of clinical settings, including by heart surgeons for patients in profound shock and by interventional cardiologists for patients who are in pre-shock or in need of prophylactic support in the cardiac catheterization lab, or cath lab. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f06%2f13%2f0001193125-07-134975.html#FIS_BUSINESS"Abiomed Inc. (ABMD:NASDAQ)
Snapshot of Abiomed Inc. (ABMD)
|
OPEN
$8.51
|
PREVIOUS CLOSE
$8.55
|
|
|
DAY HIGH
$8.69
|
DAY LOW
$8.11
|
|
|
52 WEEK HIGH
12/9/08 - $17.35
|
52 WEEK LOW
03/6/09 - $4.67
|
|
|
MARKET CAP
305.1M
|
AVERAGE VOLUME 3 mo
289.9K
|
|
|
DILUTED EPS TTM
$-0.87
|
SHARES OUTSTANDING
37.5M
|
|
|
ABMD Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Airbus' parent designs a technologically advanced artificial heart for a spin-off company, Carmat. Within three years, the device could be approved for humans
ABMD Top Compensated Officers
Executives, Board Directors
Key developments for Abiomed Inc. (ABMD)
Abiomed Inc. announced second quarter fiscal 2010 revenue of $20 million. The GAAP net loss was $7.7 million, or a loss of $0.21 per share, compared to a GAAP net loss of $6.3 million, or a loss of $0.18 per share for the second quarter of fiscal 2009. The non-GAAP net loss, after excluding stock-based compensation expense of $2.0 million and intangibles amortization expense of $0.4 million, was $5.3 million, or a loss of $0.14 per share, compared to the non-GAAP net loss of $2.5 million, or a loss of $0.08 per share, for the second quarter of fiscal 2009, after excluding stock-based compensation expense of $3.4 million and intangibles amortization expense of $0.4 million. Total revenues were $20.0 million against $20 million a year ago. Loss from operations was $7.4 million against $5.95 million a year ago. Loss before provision for income taxes was $7.4 million against $6.1 million a year ago. For the six months, the company reported net loss of $15.43 million or $0.42 per share against $15.44 million or $0.46 per share a year ago. Total revenues were $39.9 million against $36.4 million a year ago. Loss from operations was $14.9 million against $15.3 million a year ago. Loss before provision for income taxes was $14.97 million against $15.03 million a year ago. The company reaffirmed its previously issued full-year fiscal 2010 revenue guidance of growth in the range of 17% to 24% or revenues of $86 million to $91 million.
Abiomed Inc. expected to Report Q3 2010 Results on February 1, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
Abiomed Inc., Q2 2010 Earnings Call, Nov-05 2009
ABMD Competitors
| Company | Last | Change |
| Biophan Technologies Inc | $0.01 USD | +0.0005 |
| Heartware International Inc | $32.64 USD | -0.02 |
| Thoratec Corp | $29.06 USD | -0.26 |
| World Heart Corp | $4.37 USD | 0.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ABMD | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.1x |
|
| Price/Book | 2.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.5x |
|
|
ABMD |
||
ABMD transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||